Financials data is unavailable for this security.
View more
Year on year Beijing Hotgen Biotech Co Ltd 's revenues fell -84.78% from 3.56bn to 541.25m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 944.74m to 27.38m, a -97.10% decrease.
| Gross margin | 46.98% |
|---|---|
| Net profit margin | -14.33% |
| Operating margin | -12.85% |
| Return on assets | -2.13% |
|---|---|
| Return on equity | -2.03% |
| Return on investment | -2.22% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Beijing Hotgen Biotech Co Ltd fell by 250.83m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 51.95m for operations while cash used for investing totalled 161.87m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 35.25 |
|---|---|
| Tangible book value per share | 34.68 |
More ▼
Balance sheet in CNYView more
| Current ratio | 9.85 |
|---|---|
| Quick ratio | 8.95 |
| Total debt/total equity | 0.0026 |
|---|---|
| Total debt/total capital | 0.0026 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items dropped -96.98%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| Div yield(5 year avg) | 2.01% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -14.97 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 32.86 |
More ▼
